comprehensive -WSS

comprehensive

author：explore 2025-10-02 17:22:05 - browse：228

European Medicines Agency Suffers Cyber Attack in Amsterdam — Paulo Amorim / VWPics via AP Images

LONDON — This week, European regulators are considering an appeal from Amylyx Pharmaceuticals after initially recommending against approving the company’s ALS treatment — the latest potential turning point for a drug that has seen its share of ups and downs with regulatory bodies.

In June, a European Medicines Agency committee issued a negative review of Amylyx’s drug, called Albrioza, and cast doubt on whether it had demonstrated effectiveness in its pivotal study. That would have almost certainly led to a rejection by regulators, but Amylyx requested what’s called a re-examination of the opinion. On Tuesday, the EMA held a meeting on the appeal, and a decision is expected in the coming weeks.

“There are patients who are dying and they really want access to the drug,” said Evy Reviers, the chairwoman of the European Organization for Professionals and Patients with ALS, whose father has the neurological disease.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Senate panel to vote on hospitals, PBMs, prisoner care

hotspot

WSS

Continuity nursing helped my family in our darkest PICU moments

Maker of FluMist seeks to allow at

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

United colonoscopy coverage change 'may cost lives,' doctors say

Medicare details structure of new drug price negotiation program

FDA has safety concerns on CRISPR

hotspot

comprehensive

focus

In age of alternative facts, a scholarly course on calling out crap

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Wildfire smoke exposes gaps in outdoor worker protections

Readout Newsletter: XBI biotech index, Akero Therapeutics

Anesthesiologist group: stop taking Ozempic before surgery

Dobbs anniversary: the lost opportunity of abortion as health care

How one medical school became remarkably diverse

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

At least 13 dead in Texas as scorching temps continue

Eli Lilly to pay $200M for Beam’s stake in gene

knowledge

Apple is now the first public company to be valued at $3 trillion

Physician subsidies by hospitals soar in wake of No Surprises Act

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

The FDA weighs the risks of candy

Emergency medicine has repudiated 'excited delirium.' Now what?

Physician subsidies by hospitals soar in wake of No Surprises Act

knowledge

entertainment

hotspot

explore